Linked Life Data

16543674

Source:http://linkedlifedata.com/resource/pubmed/id/16543674

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2006-3-17
pubmed:abstractText
Mitiglinide is novel class of rapid-acting insulin secretagogues, which have been widely used alone or in combination with other oral hypoglycemic drugs to improve postprandial hyperglycemia in early type 2 diabetes. While mitiglinide enhances postprandial requirement of insulin, the efficacy of mitiglinide combined with insulin has yet to be established. We investigated the efficacy of mitiglinide combined with insulin glargine, the first soluble insulin analog that has a flat and prolonged effect. After control with the intensive regimen (daily aspart insulin and glargine), 30 inpatients with type 2 diabetes were switched to premeal mitiglinide combined with once daily insulin glargine (mitiglinide regimen), and daily profiles of blood glucose level were compared under each regimen. Fifteen patients showed similar control of hyperglycemia with mitiglinide regimen and intensive insulin regimen, assessed by M value (<32), while the remaining 15 showed worsening under the mitiglinide regimen. The patients who were well controlled with mitiglinide regimen were significantly younger (51.9 +/- 16.0 years, p<0.005) and heavier (body mass index: 25.7 +/- 3.3 kg/m(2), p<0.05) than those who were not (67.9 +/- 8.7 and 23.0 +/- 3.1, respectively). Moreover, insulin doses of aspart per body weight were significantly fewer in effective group than in ineffective group. Duration of diabetes was shorter in the effective group, albeit insignificantly. Previous treatment before starting intensive insulin regimen, such as insulin and sulfonylurea, was not different between the two groups. Our results suggest that mitiglinide plus insulin glargine combination therapy is useful for lowering both fasting and postprandial hyperglycemia in a subpopulation of type 2 diabetes. The long-term effects of such treatment need to be established in future studies.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0918-8959
pubmed:author
pubmed:issnType
Print
pubmed:volume
53
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
67-72
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:16543674-Adult, pubmed-meshheading:16543674-Age Factors, pubmed-meshheading:16543674-Aged, pubmed-meshheading:16543674-Blood Glucose, pubmed-meshheading:16543674-Body Mass Index, pubmed-meshheading:16543674-Diabetes Mellitus, Type 2, pubmed-meshheading:16543674-Dose-Response Relationship, Drug, pubmed-meshheading:16543674-Drug Therapy, Combination, pubmed-meshheading:16543674-Female, pubmed-meshheading:16543674-Humans, pubmed-meshheading:16543674-Hyperglycemia, pubmed-meshheading:16543674-Hypoglycemic Agents, pubmed-meshheading:16543674-Indoles, pubmed-meshheading:16543674-Insulin, pubmed-meshheading:16543674-Insulin, Long-Acting, pubmed-meshheading:16543674-Insulin Aspart, pubmed-meshheading:16543674-Isoindoles, pubmed-meshheading:16543674-Male, pubmed-meshheading:16543674-Middle Aged, pubmed-meshheading:16543674-Postprandial Period, pubmed-meshheading:16543674-Time Factors
pubmed:year
2006
pubmed:articleTitle
Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus.
pubmed:affiliation
Department of Medicine, Metabolism and Endocrinology, Juntendo University, School of Medicine, Tokyo, Japan.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Research Support, Non-U.S. Gov't